RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145

RBC Capital initiated AstraZeneca with an Outperform rating and a £145 price target, calling it the most compelling risk/reward opportunity in its European pharma coverage. The broker argues AZN's 14x P/E—its lowest in 10 years—already reflects concerns around Wainua's ATTR failure, potential Bristol Myers Squibb acquisition speculation, and 2H 2026 SERENA-4/AVANZAR trial uncertainty. RBC expects a re-rating after those catalysts resolve, citing leading peer growth, pipeline optionality, and AstraZeneca's unchanged $80 billion target.

Analysis

AZN’s valuation discount creates an asymmetric setup because the debate is concentrated in a limited number of late-stage readouts while the earnings base remains diversified across oncology, respiratory and cardiometabolic franchises. A clean resolution of the 2H26 trial overhang could drive multiple normalization toward European large-cap pharma peers, but the near-term catalyst is more likely incremental consensus upgrades as investors separate a single asset failure from the broader pipeline. The key analytical question is whether estimates for core-product durability—not headline pipeline NPV—remain intact through 2027.

The failed ATTR program is more consequential competitively for ALNY than for AZN: it reduces the probability that a new silencer mechanism expands the addressable treatment population beyond patients not adequately served by stabilizers. That should reinforce the value of established ATTR franchises and make ALNY’s next efficacy, safety and access data more important, rather than creating a broad read-through on RNAi. AMGN gains modestly from positive partnered-program data, but shared economics mean the clinical wins are unlikely to move its consolidated earnings profile materially.

A potential BMY transaction is the principal multiple cap for AZN over the next 1-3 months. Even before any formal bid, investors may discount AZN for equity issuance, leverage, patent-cliff exposure and integration risk; BMY’s low headline valuation does not automatically make the combination accretive after financing costs and lost strategic flexibility. Contrarian view: the market may be assigning too much probability to a deal that would be difficult to justify without a substantial synergy case, leaving AZN vulnerable to less downside from deal speculation than consensus assumes.

Over 6-18 months, U.S. drug-pricing policy is the larger structural risk than the cited clinical event. The relevant falsifier is a material reduction in AZN’s U.S. net-price/revenue assumptions or guidance, particularly for new launches, rather than management’s qualitative pricing commentary. Monitor quarterly product-level sales and operating-margin guidance: sustained growth without a margin giveback supports rerating; any core-franchise miss alongside deal escalation would invalidate the long thesis.

Key Decisions for Investors

• Initiate a 3-6 month long AZN position on weakness, sized as a catalyst/value trade rather than a binary trial bet. Target a rerating from the current depressed earnings multiple toward peer levels; risk is a core-sales/guidance miss or credible BMY bid, either of which should trigger reassessment rather than averaging down.
• Express the relative-value view as long AZN / short BMY over 1-3 months if acquisition speculation intensifies. AZN bears financing and integration downside while BMY captures takeover optionality; cover the short if a formal offer emerges or BMY receives a competing strategic catalyst.
• Avoid treating the ATTR failure as a standalone short signal for ALNY until its own pipeline and commercial metrics show impaired demand or mechanism-wide safety concerns. Set an alert for revised ALNY guidance, payer-access changes, or negative incremental silencer data; absent these, the read-through is insufficient for a high-conviction short.
• Maintain AMGN as a lower-beta healthcare exposure, not a direct expression of the AZN thesis. Revisit only if partnered indications translate into material revenue guidance changes, since clinical validation alone is unlikely to alter AMGN’s consolidated valuation.